DGAP-News: MeVis Medical Solutions AG: MeVis publishes final figures for fiscal year 2013 / Shares in Medis sold in April 2014

        Print
| Source: EQS Group AG
DGAP-News: MeVis Medical Solutions AG / Key word(s): Final Results
MeVis Medical Solutions AG: MeVis publishes final figures for fiscal
year 2013 / Shares in Medis sold in April 2014

24.04.2014 / 07:30

---------------------------------------------------------------------

2013 strongest year since IPO in 2007

  - Group revenues increased by 10 % year on year to EUR 14.6 m

  - Earnings before interest and taxes (EBIT) increased significantly by
    EUR 1.0 m to EUR 4,0 m

  - Net income of EUR 3.7 m (previous year EUR 2.2 m) 

  - Earnings per share increased from EUR 1.26 to EUR 2.14 

  - Liquidity increased by EUR 5.3 m to EUR 14.0 m (Dec.31, 2012: EUR 8.7
    m)

  - Sale of 41 % share in Medis in April 2014 at carrying value

Bremen, April 24, 2014 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a
leading provider of medical imaging software, today announced its final
figures for fiscal year 2013, which correspond to the preliminary figures
released on March 5, 2014.

The group revenues generated in 2013 amounted to EUR 14.6 m, up 10 %
compared to the previous year's revenues of EUR 13.3 m. The increase in
licensing business by 9 % from EUR 7.0 m to EUR 7.6 m as well as an
increase in non-recurring engineering contributions of EUR 0.5 m to EUR 0.8
m contributed to this growth. Maintenance revenues grew by 4 % to EUR 6.2
m.

The increase in revenues resulted almost entirely from the Digital
Mammography segment, where revenues rose from EUR 10.1 m to EUR 11.3 m,
while revenues in the Other Diagnostics segment grew only marginally from
EUR 3.2 m to EUR 3.3 m.

Operating costs could be reduced again in 2013 as staff costs decreased by
EUR 0.2 m from EUR 8.1 m to EUR 7.9 m and other operating expenses by as
much as EUR 0.4 m from EUR 2.3 m to EUR 1.9 m.

In 2013 the capitalization of development costs has been cut nearly in half
by EUR 1.0 m from EUR 2.4 m to EUR 1.4 m. This effect is almost entirely
offset by a decrease in depreciation of EUR 0.9 m from EUR 3.0 m to EUR 2.1
m.

For 2013 this results in an EBIT (earnings before interest and taxes) of
EUR 4.0 m, which is EUR 1.0 m higher than previous year and corresponds to
an EBIT margin of 28 % (previous year: 22 %).

After an improved financial result of EUR -0.2 m (previous year: EUR -0.6
m) and a low tax expense of EUR 0.1 m (previous year: EUR 0.2 m) the
consolidated net result came to EUR 3.7 m (previous year: EUR 2.2 m), which
corresponds to earnings per share of EUR 2.14 (previous year: EUR 1.26).

Cash and cash equivalents increased significantly in 2013 and amounted to 
EUR 14.0 m at year-end (compared to EUR 8.7 m as at December 31, 2012). In
addition to the good operating performance, the reduction of receivables
has contributed significantly to this very strong cash flow of EUR 5.3 m.

"Over the past two years we already considerably simplified the structure
of MeVis. In order to focus on our industrial customers, our online
services as well as our core fields breast, lung and liver we have sold our
41% stake in the Dutch Medis Holding B.V. to the majority stake holder and
original owner the Reiber Consultancy B.V. in April." said Dr. Robert
Hannemann, CFO of MeVis Medical Solutions AG. "The proceeds from the sale
of our shares in the amount of EUR 0.5 m approximately equals the carrying
value of the investment, so that the divestment has largely no effect on
the net income."

"Following the early extension of the existing license agreement with
Hologic until end of 2015 we substantiate our discussions with Hologic
about the further cooperation and our future support in development. We
expect to achieve a contractual agreement on this within this quarter."
added Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. "The expansion
of the industrial customers segment through broadening of the product range
for our existing customers as well as through enhanced acquisition of new
customers is the essential focus of our activities. In addition to
expanding our clinical and technological expertise in breast diagnostic we
will increasingly put or focus on the development of a lung screening
solution. We see lung screening as the market with the highest growth
potential in the near future."

The interim financial statement for the first quarter 2014 will be
published on May 19, 2014.


End of Corporate News

---------------------------------------------------------------------

24.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     MeVis Medical Solutions AG                             
             Caroline-Herschel-Str. 1                               
             28359 Bremen                                           
             Germany                                                
Phone:       +49 421 224 95 0                                       
Fax:         +49 421 224 95 999                                     
E-mail:      ir@mevis.de                                            
Internet:    http://www.mevis.de                                    
ISIN:        DE000A0LBFE4                                           
WKN:         A0LBFE                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
264281 24.04.2014